INCRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Intercure Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026

$4.46−0.11 (-2.41%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Dec 31, 2025

Total debt

195.30M ILS

135.84M ILS due within a year

Net debt

148.84M ILS

After 46.47M ILS of cash

Implied interest rate

–

FY2025 interest ÷ average debt

Interest coverage

–

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, ILS

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Intercure's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Intercure's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Aug 24, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is INCR.

Revenue growth13.1% · median 23.4%

Gross margin12.3% · median 42.7%

Operating margin-10.1% · median 7.4%

Net margin-13.2% · median -13.1%

Company	Revenue	Growth
VREOF	$511.67M	+316.7%
INCR	270.20M ILS	+13.1%
KMDA	$191.85M	+13.2%
AMRN	$186.23M	-15.1%
ELTP	$141.01M	+33.7%
IMCC	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Auditor: Somekh Chaikin
SEC CIK: 1857030

Advertisement
300 × 250